Clinical Trials Browser

Phase 1/2 × Biological Products × Clear all

NCT02529930 2022-07-13

An Exploratory Safety and Immunogenicity Study of HPV16+ Immunotherapy VB10.16 in Women With HSIL; CIN 2/3)

Phase 1/2 Completed

High Grade Cervical Intraepithelial Neoplasia